

ACCESS4ME[®] REIMBURSEMENT GUIDE



This guide provides example billing and coding information for ROLVEDON[®] including sample claim forms and information about how ACCESS4Me[®] can be a trusted resource through the navigation process.

ACCESS **4** ME[®]

Help is just a call or click away!



Communicate directly with an assigned Asserzio Specialty Pharmaceuticals Field Reimbursement Manager or Reimbursement Specialist at **866-582-2737 (866-58-CARES)** 8:00 AM to 8:00 PM (ET), Monday - Friday



Visit **ACCESS4Me.com** for online enrollment and access to tools, forms, and resources



ROLVEDON[®]
(eflapegrastim-xnst) injection
13.2 mg/0.6 mL

WHAT TO KNOW: CODING FOR ROLVEDON®

It is the provider's responsibility to code accurately and Assertio Specialty Pharmaceuticals is not responsible for a provider's coding decision. All decisions on diagnosis, the need for treatment, and the appropriateness of ROLVEDON® for a particular patient are the responsibility of the treating healthcare provider.

Coding Reference Guide for ROLVEDON

HCPCS code	Description
J1449	Injection, eflapegrastim-xnst, 0.1 mg
Billable units	
132	Billable unit for administration of one syringe
CPT® code	
96372	Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular
ICD-10-CM diagnosis code	
Varies, eg, D70(X). Specific fourth digit required; depends on medical record documentation	Codes vary according to the patient diagnosis. More than one ICD-10-CM code may apply
NDC*	
82497-132-01	10-digit code
82497-0132-01	11-digit code required by some payors for billing purposes
Revenue codes	
0636	Drugs requiring detailed coding; used in conjunction with HCPCS code
0510	Clinic visit; used in conjunction with CPT code
Modifiers	
TB modifier	Modifier for drug or biological acquired with 340B drug pricing program discount; report for informational purposes
JG modifier	Modifier for drug or biological acquired with 340B drug pricing program discount; use with each separately payable, non-pass-through 340B-acquired drug
JW modifier	Modifier to report the amount of drug or biological that is discarded and eligible for payment under the discarded drug policy
JZ modifier	Providers and suppliers are required to report the JZ modifier on all claims that bill for drugs separately payable under Medicare Part B when there is no discarded amount from single-dose containers or single-use packages. Other payors may have similar requirements




CPT=Current Procedural Terminology; HCPCS=Healthcare Common Procedure Coding System; ICD=International Classification of Diseases; NDC=National Drug Code.

*Please note that although the FDA uses a 10-digit format when registering NDCs, payors often require an 11-digit NDC format on claim forms for billing purposes. The 10-digit format is converted to an 11-digit code by adding a zero (0) in front of the second group of numbers.

ORDERING ROLVEDON®



Contact one of our authorized distributors to order ROLVEDON® and receive it by the next business day.

Distributor 	Phone 	Website 
Cencora	1-844-222-2273	cencora.com
BioCare	1-800-304-3064	biocare-us.com
Cardinal Health	1-877-453-3972	cardinalhealth.com
Cardinal Specialty Distribution	1-855-855-0708	cardinalhealth.com/en/solutions
Oncology Supply	1-800-633-7555	oncologysupply.com
McKesson Hospitals and Health Systems	1-855-625-4677	mckesson.com
McKesson Speciality Health	1-800-482-6700	mscs.mckesson.com
Morris & Dickson Specialty Distribution	1-800-388-3833	morrisdickson.com/products/specialty/

Assertio Specialty Pharmaceuticals does not recommend the use of any particular distributor.

HOW TO COMPLETE A CMS-1500 FORM FOR ROLVEDON®

It is the provider's responsibility to code accurately and Assertio Specialty Pharmaceuticals is not responsible for a provider's coding decision.

This sample is for informational and illustrative purposes only. The content herein is not intended as legal advice or to replace a medical provider's professional judgment. Assertio Specialty Pharmaceuticals does not guarantee coverage or reimbursement for any product or service. All decisions on diagnosis, the need for treatment, and the appropriateness of ROLVEDON® for a particular patient are the responsibility of the treating healthcare provider.

★ When billing unclassified codes:

Be sure to include pertinent product identifiers in Box 19. Consider attaching prescribing information, FDA-approval letter, and drug purchase invoice when filing the claim.

Box 21.

Enter the appropriate ICD-10 code(s).

Box 24. A.

Enter the NDC code for ROLVEDON (82497-132-01).*

Box 24. D.

Enter J1449.
Enter the CPT code for the injection (96372).

Box 24. F.

Enter the price of ROLVEDON.

Box 24. G.

Enter 132 units for J1449 and 1 unit for the procedure code.

HEALTH INSURANCE CLAIM FORM
APPROVED BY NATIONAL UNIFORM CLAIM COMMITTEE (NUCC) 02/12

1. MEDICARE MEDICAID TRICARE CHAMPVA GROUP HEALTH PLAN FECA OTHER
(Medicare#) (Medicaid#) (ID#/DocID#) (Member ID#) (ID#) (ID#)

2. PATIENT'S NAME (Last Name, First Name, Middle Initial)
3. PATIENT'S BIRTH DATE (MM/DD/YY) SEX (M/F)
4. INSURED'S NAME (Last Name, First Name, Middle Initial)

5. PATIENT'S ADDRESS (No., Street)
6. PATIENT RELATIONSHIP TO INSURED (Self/Spouse/Child/Other)
7. INSURED'S ADDRESS (No., Street)

8. RESERVED FOR NUCC USE
9. OTHER INSURED'S NAME (Last Name, First Name, Middle Initial)
10. IS PATIENT'S CONDITION RELATED TO:
a. OTHER INSURED'S POLICY OR GROUP NUMBER
b. RESERVED FOR NUCC USE
c. RESERVED FOR NUCC USE
11. INSURED'S POLICY GROUP OR FECA NUMBER
a. INSURED'S DATE OF BIRTH (MM/DD/YY) SEX (M/F)
b. OTHER CLAIM ID (Designated by NUCC)
c. INSURANCE PLAN NAME OR PROGRAM NAME
12. INSURANCE PLAN NAME OR PROGRAM NAME
10d. CLAIM CODES (Designated by NUCC)
13. IS THERE ANOTHER HEALTH BENEFIT PLAN? (Yes/No) *If yes, complete items 9, 9a, and 9d.*

12. PATIENT'S OR AUTHORIZED PERSON'S SIGNATURE I authorize the release of any medical or other information necessary to process this claim. I also request payment of government benefits either to myself or to the party who accepts assignment below.
13. INSURED'S OR AUTHORIZED PERSON'S SIGNATURE I authorize payment of medical benefits to the undersigned physician or supplier for services described below.

14. DATE OF CURRENT ILLNESS, INJURY, OR PREGNANCY (LMP) (MM/DD/YY) QUAL. ()
15. OTHER DATE (MM/DD/YY) QUAL. ()
16. DATES PATIENT UNABLE TO WORK IN CURRENT OCCUPATION (FROM MM/DD/YY TO MM/DD/YY)

17. NAME OF REFERRING PROVIDER OR OTHER SOURCE (17a: NAME, 17b: NPI)
18. HOSPITALIZATION DATES RELATED TO CURRENT SERVICES (FROM MM/DD/YY TO MM/DD/YY)

19. ADDITIONAL CLAIM INFORMATION (Designated by NUCC)
20. OUTSIDE LAB? (Yes/No) \$ CHARGES ()

21. DIAGNOSIS OR NATURE OF ILLNESS OR INJURY Relate A-L to service line below (24E) ICD Ind. ()
A. XXXX B. C. D. E. F. G. H. I. J. K. L.
22. RESUBMISSION CODE ORIGINAL REF. NO. ()
23. PRIOR AUTHORIZATION NUMBER ()

24. A. DATE(S) OF SERVICE	B. PLACE OF SERVICE	C. EMG	D. PROCEDURES, SERVICES, OR SUPPLIES (Explain Unusual Circumstances) CPT/HCPCS	E. DIAGNOSIS POINTER	F. \$ CHARGES	G. DATES OR UNITS	H. PRICE PER UNIT	I. ID. QUAL.	J. RENDERING PROVIDER ID.#
1. 04/24/2021 UN1			J1449	A	XX.XX	132		NPI	
2. MM/DD/YY MM/DD/YY			96372	A	XX.XX	1		NPI	
3. MM/DD/YY MM/DD/YY								NPI	
4. MM/DD/YY MM/DD/YY								NPI	
5. MM/DD/YY MM/DD/YY								NPI	
6. MM/DD/YY MM/DD/YY								NPI	

25. FEDERAL TAX ID. NUMBER () SSN/EIN ()
26. PATIENT'S ACCOUNT NO. ()
27. ACCEPT ASSIGNMENT? (Yes/No) ()
28. TOTAL CHARGE \$ ()
29. AMOUNT PAID \$ ()
30. Reval for NUCC Use ()

31. SIGNATURE OF PHYSICIAN OR SUPPLIER INCLUDING DEGREE OR CREDENTIALS (I certify that the statements on the reverse apply to this bill and are made a part thereof.)
32. SERVICE FACILITY LOCATION INFORMATION
33. BILLING PROVIDER INFO & PH # ()

NUCC Instruction Manual available at: www.nucc.org PLEASE PRINT OR TYPE APPROVED OMB-0938-1197 FORM 1500 (02-12)

* The **10-digit NDC** is the FDA format used for labeling.
The **11-digit NDC** is the standardized 5-4-2 format required for billing and claims.
Confirm with each payor their required NDC format for claims processing.

HOW TO COMPLETE A CMS-1450 FORM FOR ROLVEDON®

It is the provider's responsibility to code accurately and Assertio Specialty Pharmaceuticals is not responsible for a provider's coding decision.

This sample is for informational and illustrative purposes only. The content herein is not intended as legal advice or to replace a medical provider's professional judgment. Assertio Specialty Pharmaceuticals does not guarantee coverage or reimbursement for any product or service. All decisions on diagnosis, the need for treatment, and the appropriateness of ROLVEDON® for a particular patient are the responsibility of the treating healthcare provider.

Box 42., 43.
Enter revenue code and description.

Box 44.
Enter J1449.
Enter the CPT code for the injection (96372).

Box 46.
Enter a unit of 132 for J1449 and 1 unit for the CPT code.

Box 66.
Enter the appropriate ICD-10 code(s).

Box 80.
Include drug name, strength, dosage, route of administration, and NDC.

1		2		3a PAT. CNTRL. #		3b MED. REC. #		4 TYPE OF BILL			
5 PATIENT NAME				6 PATIENT ADDRESS				7 STATEMENT COVERS PERIOD FROM		8 THROUGH	
9 BIRTHDATE		10 SEX		11 DATE		12 ADMISSION		13 HPI		14 TYPE	
15 SRC		16 DHR		17 STAT		18		19		20	
21		22		23		24		25		26	
27		28		29		30		31		32	
33 OCCURRENCE DATE		34 OCCURRENCE DATE		35 OCCURRENCE DATE		36 OCCURRENCE DATE		37 OCCURRENCE DATE		38	
39		40		41		42		43		44	
45		46		47		48		49		50	
51		52		53		54		55		56	
57		58		59		60		61		62	
63		64		65		66		67		68	
69		70		71		72		73		74	
75		76		77		78		79		80	
81		82		83		84		85		86	
87		88		89		90		91		92	
93		94		95		96		97		98	
99		100		101		102		103		104	
105		106		107		108		109		110	
111		112		113		114		115		116	
117		118		119		120		121		122	
123		124		125		126		127		128	
129		130		131		132		133		134	
135		136		137		138		139		140	
141		142		143		144		145		146	
147		148		149		150		151		152	
153		154		155		156		157		158	
159		160		161		162		163		164	
165		166		167		168		169		170	
171		172		173		174		175		176	
177		178		179		180		181		182	
183		184		185		186		187		188	
189		190		191		192		193		194	
195		196		197		198		199		200	
201		202		203		204		205		206	
207		208		209		210		211		212	
213		214		215		216		217		218	
219		220		221		222		223		224	
225		226		227		228		229		230	
231		232		233		234		235		236	
237		238		239		240		241		242	
243		244		245		246		247		248	
249		250		251		252		253		254	
255		256		257		258		259		260	
261		262		263		264		265		266	
267		268		269		270		271		272	
273		274		275		276		277		278	
279		280		281		282		283		284	
285		286		287		288		289		290	
291		292		293		294		295		296	
297		298		299		300		301		302	
303		304		305		306		307		308	
309		310		311		312		313		314	
315		316		317		318		319		320	
321		322		323		324		325		326	
327		328		329		330		331		332	
333		334		335		336		337		338	
339		340		341		342		343		344	
345		346		347		348		349		350	
351		352		353		354		355		356	
357		358		359		360		361		362	
363		364		365		366		367		368	
369		370		371		372		373		374	
375		376		377		378		379		380	
381		382		383		384		385		386	
387		388		389		390		391		392	
393		394		395		396		397		398	
399		400		401		402		403		404	
405		406		407		408		409		410	
411		412		413		414		415		416	
417		418		419		420		421		422	
423		424		425		426		427		428	
429		430		431		432		433		434	
435		436		437		438		439		440	
441		442		443		444		445		446	
447		448		449		450		451		452	
453		454		455		456		457		458	
459		460		461		462		463		464	
465		466		467		468		469		470	
471		472		473		474		475		476	
477		478		479		480		481		482	
483		484		485		486		487		488	
489		490		491		492		493		494	
495		496		497		498		499		500	
501		502		503		504		505		506	
507		508		509		510		511		512	
513		514		515		516		517		518	
519		520		521		522		523		524	
525		526		527		528		529		530	
531		532		533		534		535		536	
537		538		539		540		541		542	
543		544		545		546		547		548	
549		550		551		552		553		554	
555		556		557		558		559		560	
561		562		563		564		565		566	
567		568		569		570		571		572	
573		574		575		576		577		578	
579		580		581		582		583		584	
585		586		587		588		589		590	
591		592		593		594		595		596	
597		598		599		600		601		602	
603		604		605		606		607		608	
609		610		611		612		613		614	
615		616		617		618		619		620	
621		622		623		624		625		626	
627		628		629		630		631		632	
633		634		635		636		637		638	
639		640		641		642		643		644	
645		646		647		648		649		650	
651		652		653		654		655		656	
657		658		659		660		661		662	
663		664		665		666		667		668	
669		670		671		672		673		674	
675		676		677		678		679		680	
681		682		683		684		685		686	
687		688		689		690		691		692	
693		694		695		696		697		698	
699		700		701		702		703		704	
705		706		707		708		709		710	
711		712		713		714		715		716	
717		718		719		720		721		722	
723		724		725		726		727		728	
729		730		731		732		733		734	
735		736		737		738		739		740	
741		742		743		744		745		746	
747		748		749		750		751		752	
753		754		755		756		757		758	
759		760		761		762		763		764	
765		766		767		768		769		770	
771		772		773		774		775		776	
777		778		779		780		781		782	
783		784		785		786		787		788	
789		790		791		792		793		794	
795		796		797		798		799		800	
801		802		803		804		805		806	
807		808		809		810		811		812	
813		814		815		816		817		818	
819		820		821		822		823		824	
825		826		827		828		829		830	
831		832		833		834		835		836	
837		838		839		840		841		842	
843		844		845		846		847		848	
849		850		851		852		853		854	
855		856		857		858		859		860	
861		862		863		864		865		866	
867		868		869		870		871		872	
873		874		875		876		877		878	
879		880		881		882		883		884	
885		886		887		888		889		890	
891		892		893		894		895		896	
897		898									


COVERAGE, CODING, AND REIMBURSEMENT FOR INJECTABLE DRUGS

ROLVEDON® coverage, coding, and reimbursement can vary depending on each patient’s treatment plan. Below is general information about each payor type and how injectable drugs are reimbursed.

Review payor contracts before billing for new drugs. **A benefits verification is an effective way to determine how ROLVEDON will be covered.**

Medicare	
Part B or Fee for Service (FFS)	Reimbursement*
<ul style="list-style-type: none"> Injectable physician-administered drugs like ROLVEDON are typically covered under the medical benefit (Part B) Some plans may offer coverage under the pharmacy benefit (Part D) 	<ul style="list-style-type: none"> Physician’s office and freestanding infusion centers <ul style="list-style-type: none"> Part B reimburses drugs based on the average sales price (ASP) For drugs with an established ASP, the rate is ASP + 6% For newly approved drugs, the rate is wholesale acquisition cost (WAC) + 3% until an ASP is established Hospital outpatient departments (non-340B entities) <ul style="list-style-type: none"> Part B reimburses drugs with pass-through status and/or J codes at WAC + 3% until an ASP is established, which will then shift reimbursement to ASP + 6% 340B entities <ul style="list-style-type: none"> Part B reimburses drugs with pass-through status and/or J codes at WAC + 3% until an ASP is established, which will then shift reimbursement to ASP + 6% Once pass-through status expires, Part B reimburses at ASP -22.5%
Part C or Medicare Advantage	Reimbursement*
<ul style="list-style-type: none"> ROLVEDON may fall under the medical benefit or pharmacy benefit Medicare Advantage plans often follow Medicare Part B recommendations in making coverage decisions but they are not required to do so Billing and coding requirements vary for these plans and may be different from Medicare Part B 	<ul style="list-style-type: none"> Reimbursement is based on individual contracts between the healthcare provider and payor Coverage and payment rates often vary among existing facility contracts Payment rates are typically based on the ASP plus model

*Rates are subject to change at any time.



Commercial insurance

Description

- ROLVEDON® may fall under the medical benefit or pharmacy benefit
- Billing and coding requirements for commercial plans can vary

Reimbursement*

- Reimbursement is based on contracts between the healthcare provider and payor
- Physician's office and freestanding infusion centers
 - Drugs are typically reimbursed based on the ASP plus model
- Hospital outpatient departments
 - Reimbursement is predominantly based on a percent of charge model in which the hospital charges a fixed percentage above acquisition cost

Medicaid

Description

- Jointly funded by federal and state governments, Medicaid coverage varies by state and plan type
- Medicaid may cover ROLVEDON under medical benefit, pharmacy benefit, or both

Reimbursement*

- Each Medicaid state agency determines its own payment rate
- Medicaid state agencies publish payment rates online

*Rates are subject to change at any time.



Approximately 81% of Medicare Part B patients have some form of supplemental insurance, which covers copays and other costs.

ACCESS4ME®: SUPPORTING PATIENT ACCESS

The ACCESS4Me® team is available to provide information to support your eligible patients throughout the access process—from benefits verification to patient assistance.



Reimbursement Programs

- Verification of Patient-Specific Insurance Benefits
- Billing and Coding Information
- Prior Authorization Assistance
 - Appeals Resources



Patient Support Services

- Bridge Program
- Copay Assistance
- Patient Assistance Program (PAP)
- Independent Charitable Foundation Information*



Resources at Your Fingertips

- User Guides
- Forms and Documents
- Reimbursement Tools
- Program Brochures

Help is just a call or click away!



Communicate directly with an assigned Assertio Specialty Pharmaceuticals Field Reimbursement Manager or Reimbursement Specialist at **866-582-2737 (866-58-CARES)** 8:00 AM to 8:00 PM (ET), Monday - Friday



Visit **ACCESS4Me.com** for online enrollment and access to tools, forms, and resources



Open your camera app and point it here to visit our website.

ACCESS4ME®

* Independent foundations have their own eligibility rules and we cannot guarantee a foundation will help you. We do not endorse or prefer any particular foundation.

The content provided in this guide is for informational purposes only and is not intended as legal advice or to replace a medical provider's professional judgment. Assertio Specialty Pharmaceuticals does not guarantee coverage or reimbursement for any product or service. All decisions on diagnosis, the need for treatment, and the appropriateness of ROLVEDON for a particular patient are the responsibility of the treating healthcare provider. This reimbursement guide is intended as a set of general guidelines and is current as of February 2026.

CPT® is a registered trademark of the American Medical Association.